Țară: Statele Unite ale Americii
Limbă: engleză
Sursă: NLM (National Library of Medicine)
MEDROXYPROGESTERONE ACETATE (UNII: C2QI4IOI2G) (MEDROXYPROGESTERONE - UNII:HSU1C9YRES)
Pharmacia & Upjohn Company LLC
MEDROXYPROGESTERONE ACETATE
MEDROXYPROGESTERONE ACETATE 150 mg in 1 mL
INTRAMUSCULAR
PRESCRIPTION DRUG
Depo-Provera CI is indicated for use by females of reproductive potential to prevent pregnancy. Limitations of Use : The use of Depo-Provera CI is not recommended as a long-term (i.e., longer than 2 years) birth control method unless other options are considered inadequate [see Dosage and Administration (2.1) and Warnings and Precautions (5.1)]. The use of Depo-Provera CI is contraindicated in the following conditions: - Known or suspected pregnancy or as a diagnostic test for pregnancy. - Active thrombophlebitis, or current or past history of thromboembolic disorders, or cerebral vascular disease [see Warnings and Precautions (5.2)] . - Known or suspected malignancy of breast [see Warnings and Precautions (5.3)] . - Known hypersensitivity to Depo-Provera CI (medroxyprogesterone acetate) or any of its other ingredients [see Warnings and Precautions (5.5)] . - Significant liver disease [see Warnings and Precautions (5.7)] . - Undiagnosed vaginal bleeding [see Warnings and Precautions (5.10)] . Depo-Provera CI
Depo-Provera CI is supplied in the following strengths and package configurations: Vials MUST be stored upright at controlled room temperature 20° to 25°C (68° to 77°F) [see USP].
New Drug Application
DEPO-PROVERA- MEDROXYPROGESTERONE ACETATE INJECTION, SUSPENSION PHARMACIA & UPJOHN COMPANY LLC ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE DEPO-PROVERA CI SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR DEPO-PROVERA CI. DEPO-PROVERA CI (MEDROXYPROGESTERONE ACETATE) INJECTABLE SUSPENSION, FOR INTRAMUSCULAR USE INITIAL U.S. APPROVAL: 1959 WARNING: LOSS OF BONE MINERAL DENSITY _SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING_. WOMEN WHO USE DEPO-PROVERA CONTRACEPTIVE INJECTION (DEPO-PROVERA CI) MAY LOSE SIGNIFICANT BONE MINERAL DENSITY. BONE LOSS IS GREATER WITH INCREASING DURATION OF USE AND MAY NOT BE COMPLETELY REVERSIBLE. (5.1) IT IS UNKNOWN IF USE OF DEPO-PROVERA CI DURING ADOLESCENCE OR EARLY ADULTHOOD, A CRITICAL PERIOD OF BONE ACCRETION, WILL REDUCE PEAK BONE MASS AND INCREASE THE RISK FOR OSTEOPOROTIC FRACTURE IN LATER LIFE. (5.1) DEPO-PROVERA CI IS NOT RECOMMENDED AS A LONG-TERM (I.E., LONGER THAN 2 YEARS) BIRTH CONTROL METHOD UNLESS OTHER OPTIONS ARE CONSIDERED INADEQUATE. (1, 5.1) RECENT MAJOR CHANGES Indications and Usage (1) 12/2020 INDICATIONS AND USAGE Depo-Provera CI is a progestin indicated for use by females of reproductive potential to prevent pregnancy. (1) Limitations of Use: The use of Depo-Provera CI is not recommended as a long-term (i.e., longer than 2 years) birth control method unless other options are considered inadequate. (1, 5.1) DOSAGE AND ADMINISTRATION The recommended dose is 150 mg of Depo-Provera CI every 3 months (13 weeks) administered by deep, intramuscular (IM) injection in the gluteal or deltoid muscle. (2.1) DOSAGE FORMS AND STRENGTHS Vials containing sterile aqueous suspension: 150 mg per mL (3) Prefilled syringes: prefilled syringes are available packaged with 22-gauge × 1 1/2 inch Terumo® SurGuard™ Needles. (3) CONTRAINDICATIONS Known or suspected pregnancy or as a diagnostic test for pregnancy. (4) Active thrombophlebitis, or current or past history of thromboembolic diso Citiți documentul complet